Sustained Virologic Response Rates of Direct Acting Antivirals in HIV Coinfected Hepatitis C Patients and Its Effect on Liver Fibrosis

Dora Lebron1, Alexandra Stang1, Alicia Lagasca1, Rabindra Ghimire1, Marysia Grzybowski2, Manal Elnablity1, Ahmed Hamed3, Paul Cook4, Dawd Siraj4
1Division of Infectious Disease, Department of Internal Medicine, Brody School of Medicine at East Carolina University, Greenville, NC
2Department of Public Health at East Carolina University, Greenville, NC
3Department of Internal Medicine Brody School of Medicine at East Carolina University, Greenville, NC
4Division of Infectious Diseases, Department of Internal Medicine, University of Wisconsin, Madison, WI

*Corresponding author: Dora Lebron, MD 2390 Hemby Lane Greenville, NC 27834, Division of Infectious Disease, Department of Internal Medicine, Brody School of Medicine at East Carolina University, Greenville, NC.

Received date: July 25, 2020; Accepted date: August 26, 2020; Published date: August 31, 2020

Citation: Dora L, Alexandra S, Alicia L, Rabindra G, Marysia G, et all. (2020) Sustained Virologic Response Rates of Direct Acting Antivirals in HIV Coinfected Hepatitis C Patients and Its Effect on Liver Fibrosis. International Journal of Clinical Case Reports and Reviews, 3(2); DOI:10.31579/2690-4861/036

Abstract

Background: Hepatitis C virus (HCV) is an important cause of chronic hepatitis with necroinflammation and fibrosis resulting in end stage liver disease and hepatocellular carcinoma. Direct acting antivirals (DAAs) are newer agents that directly interfere with the HCV lifecycle and result in high rates of sustained virologic response (SVR). We evaluated if treatment with DAAs in a real-world setting is as successful in HCV/HIV coinfected patients as it is in HCV monoinfected patients, and if some degree of fibrosis regression can be observed after completion of therapy in both groups.

Methods: We retrospectively reviewed data from HCV monoinfected and HCV/HIV coinfecte patients who received treatment from 2014-2016 at the East Carolina University Infectious Diseases clinic. The primary outcome was to compare completion and sustained virologic response rate at either 12 or 24 weeks between HCV monoinfected patients and HCV/HIV coinfe patients. The secondary outcome was to assess regression of fibrosis at either 12 or 24 weeks after completion of therapy, defined as one METAVIR stage improvement in their FibroSure™, a noninvasive biochemical test to estimate the stage of fibrosis.

Results: There were 41 patients in each group. Compared to the coinfected group, patient no show rate was higher in the monoinfected group (p=0.0346). In the HCV monoinfected group, 25 (93%) achieved either SVR 12 or 24. Two patients were non-compliant and had detectable viral load on evaluation at week 12. In the HCV/HIV coinfe group, 37 patients achieved SVR (p=0.0039). One patient in the coinfe group did not complete therapy but achieved SVR. In terms of fibrosis, 12/18 (67%) in the monoinfected group demonstrated improvement in at least 1 Metavir stage and 6/18 (33%) had no change. In the coinfe group, 8/16 (50%) patients demonstrated an improvement in FibroSure™ stage, 5/16 (31%) had no change, and 3/16 (19%) had worsening fibrosis according to FibroSure™ stage, (p=0.4867).

Conclusions: In this small, real-world cohort, HCV/HIV coinfected patients treated with DAAs had higher completion and SVR rates than HCV monoinfected patients. Treatment failures in the monoinfected group were all linked to non-adherence, whereas, more coinfected patients achieved SVR, likely related to the fact that they were regularly engaged in routine HIV care. Fibrosis regression based on FibroSure™ was observed more in monoinfected patients than those with coinfection. Although not statistically significant, at least 50% of the patients in each group had regression of fibrosis.

Key Words: direct acting antivirals; fibrosure™; hepatitis c virus; human immunodeficiency virus; metabol; sustained virologic response

Introduction

Hepatitis C virus (HCV) is a blood-borne virus that can cause chronic hepatitis. Approximately 15-45% of infected persons spontaneously clear the virus within 6 months.[1] People unable to clear the infection develop chronic hepatitis, characterized by necroinflammation accompanied by a variable degree of fibrosis, end stage liver disease, and hepatocellular carcinoma (HCC). It is estimated that 150 million people around the world have chronic HCV and the risk of developing cirrhosis in 20 years is around 15-30%.[2] Chronic hepatitis C infection has been associated with mixed cryoglobulinemia, cryoglobulinemic vasculitis, B-cell non Hodgkin lymphoma, SICCA syndrome, polyarteritis nodosa, monoclonal gammapathies, and immune thrombocytopenia. [3,4,5] Around 85% of patients with HCV will become chronically infected developing long-term complications associated with cirrhosis and extrahepatic manifestations representing a high economic burden.[6] In the United States, approximately 10% of the patients with Hepatitis C are coinfected with human immunodeficiency virus (HIV). HIV coinfected individuals are less likely to spontaneously clear the infection due to an impaired T
cell response to HCV and are at higher risk to progress to cirrhosis with HIV viremia. This rapid progression may be attributable to weaker immune response against HCV, the effect of HIV on hepatic cells, and amplified microbial translocation accelerating fibrosis. [7, 8, 9] With the introduction of the direct acting antivirals (DAAs), a new era of hepatitis C treatment has emerged. Unlike interferon, DAAs interfere with various steps of the HCV lifecycle, similar to the way antiretroviral drugs work against HIV. [10] In HCV/HIV coinfected patients, treatment with pegylated-interferon based therapy was associated with lower sustained virologic response (SVR) rates, higher rate of adverse effects and drug-drug interactions when compared to monoinfected patients. [11, 12, 13] In this small real-world cohort, we compared treatment response in HCV monoinfected patients and HCV/HIV coinfectected patients.

Changes in fibrosis after completion of therapy using the FibroSure™ stages were also evaluated in both groups.

Methods Study Design

In this retrospective study, we reviewed the medical records of 82 HCV monoinfected and HCV/ HIV coinfectected patients presenting at East Carolina University Infectious Disease Clinic from January 2014 through December 2016. All patients were either treatment-naïve or treatment-experienced with interferon +/- ribavirin and at least 18 years of age. The Institutional Review Board approved all aspects of this study. Data collected included demographics (age, sex, and race), HIV status, and HCV genotypes. Laboratory values abstracted included alanine aminotransferase (ALT), platelet count, HCV ribonucleic acid (HCV RNA) at 4 weeks and 12 weeks of treatment, also at 12 or 24 weeks after completion of therapy. Among HIV-infected patients, CD4 and HIV viral load were measured. Treatment modalities, including type of DAA therapy and antiretroviral (ART) regimens were documented. Alcohol abstinence was a requirement to qualify for treatment.

The primary outcome was to compare completion rate and sustained virologic response at either 12 (SVR12) or 24 (SVR24) weeks after completion of therapy between HCV monoinfected and HCV/ HIV coinfectected patients. The secondary outcome was to evaluate fibrosis progression and compare it between both groups using HCV FibroSure™ assay. This is a noninvasive biochemical test that measures liver fibrosis activity. The FibroSure™ results correspond to the METAVIR scoring system for stage of fibrosis. It is based on a 5-point scale from 0 to 4 for the stage of liver fibrosis. METAVIR classifications recorded were F0, no fibrosis/ F1, portal fibrosis without septa/ F2, portal fibrosis with few septa/ F3, numerous septa without cirrhosis/ F4, cirrhosis. Baseline fibrosis was determined and dichotomized (≤F2 for mild fibrosis and >F3 for advanced fibrosis). FibroSure™ was obtained at baseline and either 12 or 24 weeks following treatment. Improvement in fibrosis was defined as one METAVIR stage improvement in FibroSure™ from baseline to either 12 or 24 weeks after completion of therapy (FibroSure™ stage at baseline (FB) - FibroSure™ stage at SVR12 or 24 (FSVR) = delta (Δ) FibroSure™ stage). Changes in fibrosis were defined as: (Δ) FibroSure™ stage ≤0 - Part of the equation - continuity - worsening fibrosis, (Δ) FibroSure™ stage =0-0.5 - no change and (Δ) FibroSure™ stage ≥1 - improvement.

Statistical Analysis

Chi square test and Fisher’s Exact Test were used for categorical variables and to determine statistical significance between HCV monoinfected and HCV/HIV coinfectected groups for completion of treatment, SVR 12 or 24, and changes in fibrosis. Student t-test was used for continuous variables. For all statistical analyses, a 0.05 level of significance was used, and all p- values were two-sided. Statistical analysis was performed using GraphPad Prism, version 7.0d.

Results

Study Population

We identified 82 HCV infected patients, 50% (n=41) of which were coinfectected with HIV (Figure 1). The overall median age was 60 years (Range, 32-73). Majority of the patients were African-American (68.3%), and male (59.5%). While age was not different by sex, it was different by race: African-Americans were, on average, 60.2 years (SD, 6.4), whites, 54 years (SD, 7.1), and other, 57 years (SD, 8.3), p<0.0001.

HCV Monoinfected versus HCV/HIV Coinfected Patients

As seen in Table 1, the median HCV viral load in the monoinfected group was 2,961,050 IU/mL (range: 54,796-30,173,000) compared to the median HCV viral load in coinfectected group that was 1,868,300 IU/mL with a range 19,610-48,999,970 (p=0.158). In the HCV/HIV coinfectected group, most patients were virally suppressed with 97.5% of the patients with a viral load <100 copies/mL and 1 patient with 370 copies/mL. Median CD4 count was 561 k/µL with a range (81-1421). Only 2 patients had CD4 <200 and both had undetectable HCV viral load at completion of therapy.

FibroSure™ results were divided as < F2 for mild fibrosis and > F3 for advanced fibrosis. In the monoinfected group, 49% had mild fibrosis and 51% had advanced fibrosis at baseline. Meanwhile, in the coinfectected group, 41% had mild fibrosis and a higher percentage, 59% had advanced fibrosis (p=0.657). Regarding DAA regimens, 78% of the patients were treated with ledipasvir/sofosbuvir (see Table 2) as 67% of the patients had genotype 1a. Twelve percent of the patients in the monoinfected group were treatment experienced vs 15% in the coinfectected group.

SVR in HCV Monoinfected versus HCV/HIV Coinfected Patients

From the 41 patients in the monoinfected group, data was collected from 27 patients (see Figure 1). Fourteen patients were not evaluated for SVR 12 or 24 as they lost follow up, but 13/14 patients were undetectable at either 4, 8 or 12 weeks of treatment. From the 27 patients that followed up, 25 (93%) achieved either SVR 12 or 24. Two patients (7%) had detectable viral load at completion of therapy. In the HIV/HCV coinfectected group, data was obtained from 37 patients, 4 patients lost follow up. One patient didn’t complete therapy but continued follow up. The 4 patients that lost follow up had undetectable viral load at either 4, 8 or 12 weeks of treatment. The coinfectected patient that didn’t complete therapy had a HCV viral load of 252,590 IU/mL and achieved SVR after receiving 4 weeks of therapy. All 37 (100%) patients in the coinfectected group that followed up had documented SVR 12 or 24.

Changes in Fibrosis in HCV Monoinfected versus HCV/HIV Coinfected

In terms of fibrosis in the monoinfected group, FibroSure™ after SVR either at 12 or 24 weeks was collected from 18 patients. Twelve patients (67%) demonstrated improvement in at least one METAVIR stage in FibroSure™ and 6 (33%) had no changes in FibroSure™. Worsening of fibrosis was not observed in the monoinfected group at either SVR 12 or 24 weeks. In the HIV/HCV coinfectected group, FibroSure™ at either 12 or 24 weeks of completion of therapy was obtained in 16 patients. Eight patients (50%) demonstrated improvement of fibrosis, 5 (31%) had no changes in FibroSure™ stage and 3 (19%) had worsening of fibrosis according to FibroSure™ stage (See Figure 2). The three patients that had worsening fibrosis were 61a, 63a and 63b. 58 years or older with CD4 count above 350/µL, 2 of them had HIV undetectable viral load, and 1 had 350 copies/mL. HCV viral load in these 3 patients ranged from African-American.
2,743,110 - 5,294,540 IU/mL, and antiretroviral (ARV) regimen consisted of an integrase inhibitor (INSTI) and 2 nucleoside reverse transcriptase inhibitors (NRTIs).

82 patients included

41 HCV Monoinfected

27 completed treatment and followed up for SVR

9 lost follow up after completion of therapy

5 lost follow up before completion of therapy

41 HCV/HIV Coinfected

4 lost follow up after completion of therapy

36 completed therapy and followed up for SVR

1 did not complete therapy but achieved SVR

Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus.

Figure 1: Patient flow chart of HCV monoinfected and HCV/HIV coinfected patients.

<table>
<thead>
<tr>
<th>Patient Characteristics</th>
<th>HCV monoinfected, n=41</th>
<th>HCV/HIV coinfected, n=41</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex (%)</td>
<td>21 (51)</td>
<td>28 (68)</td>
<td>.176</td>
</tr>
<tr>
<td>Age, median (range)</td>
<td>60 (32-71)</td>
<td>60 (47-73)</td>
<td>.652</td>
</tr>
<tr>
<td>Race: AA (%)</td>
<td>22 (54)</td>
<td>34 (83)</td>
<td>.008</td>
</tr>
<tr>
<td>White/other (%)</td>
<td>16/3 (46)</td>
<td>6/1 (17)</td>
<td></td>
</tr>
<tr>
<td>ALT, IU/L median (range)</td>
<td>53 (10-399)</td>
<td>38 (8-183)</td>
<td>.131</td>
</tr>
<tr>
<td>PLT k/µL, mean (SD)</td>
<td>224.3 (92.9)</td>
<td>175.0 (74.9)</td>
<td>.0098</td>
</tr>
<tr>
<td>HCV viral load, median (range), IU/mL</td>
<td>2,961,050 (54,796-30,173,000)</td>
<td>1,262,530 (19,610-48,999,970)</td>
<td>.158</td>
</tr>
<tr>
<td>CD4 /µL, median (range)</td>
<td>N/A</td>
<td>561 (81-1421)</td>
<td>n/a</td>
</tr>
<tr>
<td>HIV viral load, copies/mL (%) &lt;20</td>
<td>N/A</td>
<td>33 (80)</td>
<td>n/a</td>
</tr>
<tr>
<td>&gt;20 &lt;100</td>
<td>N/A</td>
<td>7 (17.5)</td>
<td>n/a</td>
</tr>
<tr>
<td>&gt;100</td>
<td>N/A</td>
<td>1 (2.5)</td>
<td>n/a</td>
</tr>
<tr>
<td>FibroSure® Baseline (%)</td>
<td>≤ F2</td>
<td>20 (49)</td>
<td>.657</td>
</tr>
<tr>
<td></td>
<td>≥ F3</td>
<td>21 (51)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AA, African American; ALT, alanine aminotransferase; HCV, hepatitis C virus; HIV, human immunodeficiency virus, PLT, platelets.

Table 1: Baseline Characteristics

<table>
<thead>
<tr>
<th>DAA Regimens</th>
<th>Total n=82 (%)</th>
<th>HCV monoinfected, n=41 (%)</th>
<th>HCV/HIV coinfected, n=41 (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total Genotype</td>
<td>Total Genotype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDV/SOF</td>
<td>64(78)</td>
<td>31(76)</td>
<td>1a – 27(65.8)</td>
<td>.79</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1b – 3 (7.3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4 – 1 (2.4)</td>
<td></td>
</tr>
<tr>
<td>Other Regimens</td>
<td>18(22)</td>
<td>10(24)</td>
<td>1a – 4 (10)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1b – 2 (4.8)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2 – 3 (7.3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3 – 1 (2.4)</td>
<td></td>
</tr>
<tr>
<td>Treatment Experienced (%)Y</td>
<td>11(14)</td>
<td>5(12)</td>
<td>6(15)</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Abbreviations: DAA, direct acting antiviral; HCV, hepatitis C virus; HIV, human immunodeficiency virus; LDV, ledipasvir; SOF, sofosbuvir.

Table 2: DAA Regimens and HCV Genotypes
Discussion:

This small cohort provides real world data about the efficacy of DAAs in HCV monoinfected, but more importantly, in HCV/HIV coinfected patients. In previous clinical trials where HCV monoinfected patients were treated with interferon-based and ribavirin therapy, SVR rates ranged from 35% to 50% in genotypes 1 or 4, and up to 80% in genotypes 2 or 3. [14, 15] These regimens were associated with increased costs, poor tolerability, and adverse effects. [11, 12] In HCV/HIV coinfected patients, poorer responses were documented and higher rates of adverse effects were observed. [16,19] Not only low SVR rates, but also progression of HCV-related liver damage including fibrosis became a major area of concern, especially in the era prior to DAAs. Factors that contribute to worsening prognosis besides HIV seropositivity include alcohol consumption, older age at the time of HCV infection, and CD4 count < 200 cells/mm³, which are also associated with a higher rate of fibrosis progression. [20,22]

In this study, HCV/HIV coinfected patients treated with DAAs demonstrated higher SVR rates than HCV monoinfected patients with overall well tolerability. Our study correlates with multiple other studies where coinfected patients, in real world setting achieved high SVR rates. Del Bello, et al published data with sofosbuvir containing regimens in which coinfected patients achieved high SVR rates with minimal adverse effects. SVR rates in coinfected patients did not vary with ARV regimen used. [23] In ALLY-2 study, SVR 12 was achieved in 97% or more patients receiving any ARV regimen. [24] The ION 4 study with coinfected patients documented high rates of sustained virologic response that ranged from 96 to 100%. [25] In the PHOTON-1 trial, 67-88% of treatment-naive participants achieved SVR12, while among treatment-experienced participants, 92-94% achieved SVR12. [26] In our study, 11 patients were treatment experienced, and all of them achieved SVR at 12 or 24 independently of HIV coinfection.

More patients in the monoinfected group did not attend all of the scheduled appointments as compared with the coinfected group. In the HCV monoinfected group, 25 (93%) achieved either SVR 12 or 24. Two patients were non-compliant and had detectable viral load on evaluation at week 12. In the HCV/HIV coinfected group, 37 patients achieved SVR, while interestingly one patient in the HCV/HIV coinfected group received only 4 weeks of therapy but had undetectable viral load 4 weeks and remained undetectable to date.

Other studies have shown different results due to poor compliance in HIV coinfected patients. Lakshmi et al concluded that real world HCV cure rates with DAAs in HCV/HIV coinfection were lower than those seen in clinical trials. In their patients, cure was associated with attendance to follow up clinic visits and use of an integrase inhibitor based HIV regimen. Cure was achieved in 83.3%. [27] In our study, more HCV/HIV coinfected patients completed therapy and followed up (88% vs 66%, respectively) and achieved SVR rates compared to monoinfected patients (88% vs 61%). We feel that this phenomenon is due to coinfected patients being already engaged in HIV care through Ryan White Program.

Before DAAs era, African-Americans had poorer response rates to pegylated interferon and ribavirin compared to Caucasians (28% vs 52%, respectively). [28,30] For this reason, AA patients with HCV/HIV coinfection were associated with a lower likelihood of receiving treatment for HCV. [31] In our clinic population, the AA population with HCV/HIV coinfection comprises a higher number than Caucasians. Compared to the mono-infected group, the co-infected population was composed of more AAs. In terms of ARV therapy, an INSTI with NRTI backbone was the most common regimen used due to safety and less drug-drug interactions (see Appendix Tables 3 and 4).

Table 3: SOF/LDV and ART Regimens

<table>
<thead>
<tr>
<th>ART Regimen</th>
<th>SOF/LDV N=33 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RPV/FTC/TDF</td>
<td>5 (15)</td>
</tr>
<tr>
<td>NVP/ABC/3TC</td>
<td>1 (3)</td>
</tr>
<tr>
<td>ATV/ABC/3TC</td>
<td>1 (3)</td>
</tr>
<tr>
<td>DRV/r/INSTI</td>
<td>3 (9)</td>
</tr>
<tr>
<td>INSTI/NRTI/NRTI</td>
<td>22 (67)</td>
</tr>
</tbody>
</table>

Abbreviations: ABC, abacavir; ART, antiretroviral therapy; ATV, atazanavir; c, cobicistat; DRV/r, darunavir/ritonavir; FTC, Emtricitabine; INSTI, integrase strand transfer inhibitors; LDV, ledipasvir; NRTI, nucleoside reverse transcriptase inhibitor, NVP, nevirapine; RPV, rilpivirine SOF, sofosbuvir; TDF, tenofovir disoproxil fumarate; VEL, velpatavir; 3TC, lamivudine

Can lower the table to have more space between text and table
It is known that HIV enhances liver damage progression and worsening fibrosis with more aggressive course of liver disease in coinfected patients. As DAAs have only recently become available, there is not enough data about the effects of SVR on liver fibrosis in this population. [33] In our study, at SVR 12 or 24 weeks, at least 50% of patients in both groups demonstrated improvement in liver fibrosis defined as one Metavir stage improvement based on FibroSure™ stages. More patients in the monoinfected group demonstrated improvement in fibrosis although not statistically significant. There was no worsening fibrosis in the monoinfected patients compared to a 19% in the coinfected group possibly due to the effect of HIV on liver fibrosis despite viral suppression or antiretroviral therapy. Two of the coinfected patients with worsening fibrosis had undetectable HIV viral load, while the patient that had 1.5 worsening fibrosis, had 370 copies/mL. This is consistent with a study that showed accelerated fibrosis in HIV coinfected patients even if HIV replication is under control by ARVs.[8] As newer and better DAAs become available, and more data on SVR and liver fibrosis becomes available, further studies with larger sample size would be needed to study long-term effects of SVR on liver fibrosis in this population.

Another study evaluated ELF scores and FibroScan® in 32 HCV-infected patients in Germany treated with SOF (93.8% SVR12). The study found biochemical response within 4 weeks and significant decrease from baseline to 12-week post-treatment follow-up in ELF and FibroScan® measurements, indicating improvement of the dynamics of liver fibrosis. [33] In our study, at SVR 12 or 24 weeks, at least 50% of patients in both groups demonstrated improvement in liver fibrosis defined as one Metavir stage improvement based on FibroSure™ stages. More patients in the monoinfected group demonstrated improvement in fibrosis although not statistically significant. There was no worsening fibrosis in the monoinfected patients compared to a 19% in the coinfected group possibly due to the effect of HIV on liver fibrosis despite viral suppression or antiretroviral therapy. Two of the coinfected patients with worsening fibrosis had undetectable HIV viral load, while the patient that had 1.5 worsening fibrosis, had 370 copies/mL. This is consistent with a study that showed accelerated fibrosis in HIV coinfected patients even if HIV replication is under control by ARVs.[8] As newer and better DAAs become available, and more data on SVR and liver fibrosis becomes available, further studies with larger sample size would be needed to study long-term effects of SVR on liver fibrosis in this population.
Our study has many limitations. Small sample size could skew the results that we have demonstrated here in larger studies. Use of certain hepatotoxic substances including over the counter medications, routine medications and alcohol could contribute to worsening of fibrosis, but we were unable to take these into account. We did not routinely obtain serum alcohol levels to know if participants used alcohol regularly. FibroSure™ as a biomarker has its limitations when compared to elastography or biopsy for the assessment of fibrosis. As assessment of fibrosis after HCV treatment is not part of the American Association for the Study of Liver Disease (AASLD) guidelines, not all patients had the opportunity to obtain a FibroSure™ at 12 or 24 weeks after completion of therapy due to limited economic resources.

Conflict of interest:
Dora Lebron, MD – none
Manal Elnabtity, PharmD - none
Alexandra Stang, MD – none
Ahmed Hamed, MD - none
Alicia Lagasca, MD – none
Marysia Grzybowski - none
Rabindra Ghimire, MD – none
Dawd Siraj, MD – not known
Paul Cook, MD - PI for Gilead, Affinergy, Leonard-Meron Biosciences
No financial support

Authors Contribution:
Dora Lebron – corresponding author
Manal Elnabtity - data curation
Alexandra Stang - data curation
Ahmed Hamed - data curation
Alicia Lagasca - supervising
Marysia Grzybowski - statistics
Rabindra Ghimire - supervising, editing
Dawd Siraj - supervising
Paul Cook - supervising, editing

References: